Cycleave polymerase chain reaction method is practically applicable for V-Ki-ras2 Kirsten rat sarcoma viral oncogene homolog (KRAS)/V-raf murine sarcoma viral oncogene homolog B1 (BRAF) genotyping in colorectal cancer

Translational Research

Volumn 156, Issue 2, 2010, Pages 98-105

  Yokota, Tomoya ^a   Shibata, Noriko ^a   Ura, Takashi ^a   Takahari, Daisuke ^a   Shitara, Kohei ^a   Muro, Kei ^a   Yatabe, Yasushi ^a  

^a AICHI CANCER CENTER HOSPITAL   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

B RAF KINASE; FORMALDEHYDE; K RAS PROTEIN; RNA DIRECTED DNA POLYMERASE;

ACCURACY; ARTICLE; CANCER PATIENT; COLON BIOPSY; COLORECTAL CANCER; CONTROLLED STUDY; CYCLEAVE POLYMERASE CHAIN REACTION; CYTOLOGY; GENE MUTATION; GENE SEQUENCE; GENOTYPE; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; INTERMETHOD COMPARISON; MUTATIONAL ANALYSIS; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; RECTUM BIOPSY; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TUMOR BIOPSY;

EID: 77955387254     PISSN: 19315244     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.trsl.2010.05.007     Document Type: Article

References (25)

1. C. Arteaga Targeting HER1/EGFR: a molecular approach to cancer therapy Semin Oncol 30 2003 3 14
2. C.L. Arteaga Overview of epidermal growth factor receptor biology and its role as a therapeutic target in human neoplasia Semin Oncol 29 2002 3 9
3. L.B. Saltz, N.J. Meropol, P.J. Loehrer Sr, M.N. Needle, J. Kopit, and R.J. Mayer Phase II trial of cetuximab in patients with refractory colorectal cancer that expresses the epidermal growth factor receptor J Clin Oncol 22 2004 1201 1208
4. D. Cunningham, Y. Humblet, and S. Siena Cetuximab monotherapy and cetuximab plus irinotecan in irinotecanrefractory metastatic colorectal cancer N Engl J Med 351 2004 337 345
5. Jonker DJ, Karapetis CS, Moore M, et al. Randomized Phase III trial of cetuximab monotherapy plus best supportive care (BSC) versus BSC alone in patients with pretreated metastatic epidermal growth factor receptor (EGFR)-positive colorectal carcinoma: a trial of the National Cancer Institute of Canada Clinical Trials Group (NCIC CTG) and the Australasian Gastro-Intestinal Trials Group (AGITG). Proceedings of the American Association for Cancer Research Annual Meeting, 2007.
6. K.Y. Chung, J. Shia, and N.E. Kemeny Cetuximab shows activity in colorectal cancer patients with tumors that do not express the epidermal growth factor receptor by immunohistochemistry J Clin Oncol 23 2005 1803 1810
7. T.D. Barber, B. Vogelstein, K.W. Kinzler, and V.E. Velculescu Somatic mutations of EGFR in colorectal cancers and glioblastomas N Engl J Med 351 2004 2883
8. K.W. Kinzler, and B. Vogelstein Colorectal tumors K.W. Kinzler, B. Vogelstein, The genetic basis of human cancer 1999 McGraw-Hill London, UK 565 587
9. P.T. Wan, M.J. Garnett, and S.M. Roe Mechanism of activation of the RAF-ERK signaling pathway by oncogenic mutations of B-RAF Cell 116 2004 855 867
10. E. Van Cutsem, I. Lang, and G. D'haens KRAS status and efficacy in the first-line treatment of patients with metastatic colorectal cancer (mCRC) treated with FOLFIRI with or without cetuximab: the CRYSTAL experience J Clin Oncol 2008 26
11. C. Bokemeyer, I. Bondarenko, and J.T. Hartmann KRAS status and efficacy of first-line treatment of patients with metastatic colorectal cancer (mCRC) with FOLFOX with or without cetuximab: the OPUS experience J Clin Oncol 2008 26
12. C.S. Karapetis, S. Khambata-Ford, and D.J. Jonker K-ras mutations and benefit from cetuximab in advanced colorectal cancer N Engl J Med 359 2008 1757 1765
13. F. Di Nicolantonio, M. Martini, and F. Molinari Wild-type BRAF is required for response to panitumumab or cetuximab in metastatic colorectal cancer J Clin Oncol 26 2008 5705 5712
14. S. Benvenuti, A. Sartore-Bianchi, and F. Di Nicolantonio Oncogenic activation of the RAS/RAF signaling pathway impairs the response of metastatic colorectal cancers to anti-epidermal growth factor receptor antibody therapies Cancer Res 67 2007 2643 2648
15. J. Souglakos, J. Philips, and R. Wang Prognostic and predictive value of common mutations for treatment response and survival in patients with metastatic colorectal cancer Br J Cancer 101 2009 465 472
16. Y. Yatabe, T. Hida, Y. Horio, T. Kosaka, T. Takahashi, and T. Mitsudomi A rapid, sensitive assay to detect EGFR mutation in small biopsy specimens from lung cancer J Mol Diagn 8 2006 335 341
17. H. Sakamoto, J. Shimizu, and Y. Horio Disproportionate representation of KRAS gene mutation in atypical adenomatous hyperplasia, but even distribution of EGFR gene mutation from preinvasive to invasive adenocarcinomas J Pathol 212 2007 287 294
18. COSMIC (Catalogue of somatic mutations in cancer) database. Available at: http://www.sanger.ac.uk/genetics/CGP/cosmic/.
19. E.E. Mancl, J.M. Kolesar, and L.C. Vermeulen Clinical and economic value of screening for Kras mutations as predictors of response to epidermal growth factor receptor inhibitors Am J Health Syst Pharm 66 2009 2105 2112
20. C. Williams, F. Pontén, and C. Moberg A high frequency of sequence alterations is due to formalin fixation of archival specimens Am J Pathol 155 1999 1467 1471
21. Pao William, and Ladanyi Marc Epidermal growth factor receptor mutation testing in lung cancer: searching for the ideal method Clin Cancer Res 13 2007 4954 4955
22. H. Nagahara, K. Mimori, and M. Ohta Somatic mutations of epidermal growth factor receptor in colorectal carcinoma Clin Cancer Res 11 2005 1368 1371 (Pubitemid 40315215)
23. M.-S. Tsao, A. Sakurada, and J.-C. Cutz Erlotinib in lung cancer - molecular and clinical predictors of outcome N Engl J Med 353 2005 133 144
24. A. Marchetti, L. Felicioni, and F. Buttitta Assessing EGFR mutations N Engl J Med 354 2006 526 528
25. M. Akbari, M.D. Hansen, J. Halgunset, F. Skorpen, and H.E. Krokan Low copy number DNA template can render polymerase chain reaction error prone in a sequence-dependent manner J Mol Diagn 7 2005 36 39